New therapeutic agent proves more effective treatment for advanced prostate cancer

Thursday, January 5, 2017 - 11:01 in Health & Medicine

A German multicenter study, initiated by the German Society of Nuclear Medicine, demonstrates that lutetium-177 (Lu-177)-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). ... Read more

Read the whole article on Science Blog

More from Science Blog

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net